In a report issued on May 10, Joseph Schwartz from SVB Securities reiterated a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $9.58, close to its 52-week low of $8.86. According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.7% and a 24.1% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals. Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $24.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-aurinia-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral